IP Library › Granted Patent US 11,771,762
Granted Patent B2
US 11,771,762 · App. 16/848,752 · Granted Oct 3, 2023

Anti-ErbB3 antibodies and uses thereof

Inventors: Christopher Daly (New York, NY); Douglas MacDonald (New York, NY); Xunbao Duan (Horsham, PA)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K39/39558A61K31/517A61K31/5377A61K39/3955C07K16/2863C07K16/3023C07K16/3046C07K16/3053C07K16/32C07K16/40A61K2039/505A61K2039/507C07K2317/21C07K2317/34C07K2317/56C07K2317/565C07K2317/73C07K2317/76C07K2317/77C07K2317/92C12N5/10C12N15/63C12N2510/00C12N2800/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,771,762
App. No.
16/848,752
Granted
Oct 3, 2023
Kind
B2
Abstract

The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Claims (25)

1. An isolated host cell comprising: (a) a nucleic acid molecule encoding a heavy chain variable region (HCVR) of an antibody that binds ErbB3, wherein the HCVR comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 324, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 326, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 328; and (b) a nucleic acid molecule encoding a light chain variable region (LCVR) of an antibody that binds ErbB3, wherein the LCVR comprises a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 332, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 336.

2. The isolated host cell of claim 1 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 322.

3. The isolated host cell of claim 1 , wherein the nucleic acid molecule encoding the HCVR comprises a nucleotide sequence having at least 95% identity to SEQ ID NO: 321.

4. The isolated host cell of claim 3 , wherein the nucleic acid molecule encoding the HCVR comprises the nucleotide sequence of SEQ ID NO: 321.

5. The isolated host cell of claim 1 , wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 330.

6. The isolated host cell of claim 1 , wherein the nucleic acid molecule encoding the LCVR comprises a nucleotide sequence having at least 95% identity to SEQ ID NO: 329.

7. The isolated host cell of claim 6 , wherein the nucleic acid molecule encoding the LCVR comprises the nucleotide sequence of SEQ ID NO: 329.

8. A method of producing an antibody that binds ErbB3, the method comprising:

culturing the host cell of claim 1 under conditions in which the antibody is expressed; and

recovering the antibody so expressed.

9. An isolated nucleic acid molecule comprising a first nucleic acid sequence encoding a HCVR of an antibody that binds ErbB3 and a second nucleic acid sequence encoding a LCVR of an antibody that binds ErbB3, wherein the first nucleic acid sequence encodes a HCVR comprising the amino acid sequence of SEQ ID NO: 322, and wherein the second nucleic acid sequence encodes a LCVR comprising the amino acid sequence of SEQ ID NO: 330.

10. The isolated nucleic acid molecule of claim 9 , wherein the first nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 321 and the second nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 329.

11. An expression vector comprising the nucleic acid molecule of claim 9 .

12. An isolated host cell comprising the expression vector of claim 11 .

13. A method of producing an antibody that binds ErbB3, the method comprising:

culturing the host cell of claim 12 under conditions in which the antibody is expressed; and

recovering the antibody so expressed.

14. An isolated host cell comprising: (a) an expression vector comprising a nucleic acid molecule encoding a heavy chain variable region (HCVR) of an antibody that binds ErbB3, wherein the HCVR comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 324, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 326, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 328; and (b) an expression vector comprising a nucleic acid molecule encoding a light chain variable region (LCVR) of an antibody that binds ErbB3, wherein the LCVR comprises a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 332, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 336.

15. The isolated host cell of claim 14 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 322.

16. The isolated host cell of claim 14 , wherein the nucleic acid molecule encoding the HCVR comprises the nucleotide sequence of SEQ ID NO: 321.

17. The isolated host cell of claim 14 , wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 330.

18. The isolated host cell of claim 14 , wherein the nucleic acid molecule encoding the LCVR comprises the nucleotide sequence of SEQ ID NO: 329.

19. A method of producing an antibody that binds ErbB3, the method comprising:

culturing the host cell of claim 14 under conditions in which the antibody is expressed; and

recovering the antibody so expressed.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2023
From: DALY, CHRISTOPHER; MACDONALD, DOUGLAS; DUAN, XUNBAO
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 063934/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: DALY, CHRISTOPHER; MACDONALD, DOUGLAS; DUAN, XUNBAO
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 056040/0420 →
Continuity (8)
Continuation 15793756 · Oct 25, 2017
Continuation 15011978 · Feb 1, 2016
Continuation 14308527 · Jun 18, 2014
Division 13623885 · Sep 21, 2012
Provisional Application 61614565 · Mar 23, 2012
Provisional Application 61557460 · Nov 9, 2011
Provisional Application 61541312 · Sep 30, 2011
Related Publication 20200276307A1 · Sep 3, 2020